| 183 Current Role of Radiotherapy for Renal-Cell Carcinoma: Review Natalia Dengina, Ilya Tsimafeyeu, Timur Mitin 188 Primary Choriocarcinoma of the Bladder: A Case Report and … A Erbersdobler, TH Ho, R Nunez-Nateras, YX Hou, AH Bryce, ... | | |
| 8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness JE Eckel-Passow, H Yan, ML Kosel, D Serie, PA Decker, RB Jenkins, ... BMC urology 20, 1-9, 2020 | 1 | 2020 |
| A comprehensive pan-cancer molecular study of gynecologic and breast cancers AC Berger, A Korkut, RS Kanchi, AM Hegde, W Lenoir, W Liu, Y Liu, ... Cancer cell 33 (4), 690-705. e9, 2018 | 582 | 2018 |
| A framework for living evidence synthesis in cancer: Living, interactive network meta-analysis for first-line treatment of metastatic renal cell carcinoma (mRCC). IB Riaz, H He, AJ Ryu, R Siddiqi, SAA Naqvi, Y Yao, M Husnain, ... Journal of Clinical Oncology 39 (6_suppl), 335-335, 2021 | | 2021 |
| A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma IB Riaz, H He, AJ Ryu, R Siddiqi, SAA Naqvi, Y Yao, M Husnain, ... European urology 80 (6), 712-723, 2021 | 50 | 2021 |
| A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC). M Kohli, R Qin, L Wang, H Sicotte, R Carlson, W Tan, RE Jimenez, ... Journal of Clinical Oncology 33 (15_suppl), 5056-5056, 2015 | | 2015 |
| A MOLECULAR SCORING ALGORITHM TO PREDICT SURVIVAL IN METASTATIC RENAL CELL CARCINOMA: PD52-11 B Leibovich, D Serie, T Ho, J Cheville, R Joseph, M Parasramka, ... Journal of Urology 197 (4), e993-e994, 2017 | | 2017 |
| A multidisciplinary biospecimen bank of renal cell carcinomas compatible with discovery platforms at Mayo Clinic, Scottsdale, Arizona TH Ho, RN Nateras, H Yan, JG Park, S Jensen, C Borges, JH Lee, ... PloS one 10 (7), e0132831, 2015 | 13 | 2015 |
| A pan-cancer analysis of enhancer expression in nearly 9000 patient samples H Chen, C Li, X Peng, Z Zhou, JN Weinstein, SJ Caesar-Johnson, ... Cell 173 (2), 386-399. e12, 2018 | 287 | 2018 |
| A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-β superfamily A Korkut, S Zaidi, RS Kanchi, S Rao, NR Gough, A Schultz, X Li, ... Cell systems 7 (4), 422-437. e7, 2018 | 152 | 2018 |
| A Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC) DF McDermott, RW Joseph, T Ho, U Vaishampayan, S Ali, M Matrana, ... Annals of Oncology 28, v317-v318, 2017 | 2 | 2017 |
| A Phase 1 Dose Finding Study of X4P-001 (An Oral CXCR4 Inhibitor) and Axitinib in Patients with Advanced Renal Cell Carcinoma D McDermott, R Joseph, T Ho, U Vaishampayan, S Ali, M Matrana, R Alter, ... therapy 4, 5, 0 | | |
| A Phase 1 Dose Finding Study of X4P-001 (An Oral CXCR4 Inhibitor) and Axitinib in Patients with Advanced Renal Cell Carcinoma M Atkins, R Joseph, T Ho, U Vaishampayan, S Ali, M Matrana, R Alter, ... | 7 | 2018 |
| A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma UN Vaishampayan, DF McDermott, MR Matrana, SY Rha, AJ Zurita, ... J Clin Oncol 36, 2018 | 11 | 2018 |
| A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to … L Wang, SM Dehm, DW Hillman, H Sicotte, W Tan, M Gormley, ... Annals of Oncology 29 (2), 352-360, 2018 | 79 | 2018 |
| A study of combination Bicalutamide and Raloxifene for patients with castration-resistant prostate Cancer TH Ho, R Nunez-Nateras, YX Hou, AH Bryce, DW Northfelt, AC Dueck, ... Clinical Genitourinary Cancer 15 (2), 196-202. e1, 2017 | 14 | 2017 |
| A study of thymidylate synthase gene expression as a biomarker for the treatment of esophageal adenocarcinoma. S Beamer, Z Gatalica, J Xiu, DE Jaroszewski, M Stanton, R Pai, M Krishna, ... Journal of Clinical Oncology 35 (15_suppl), e15563-e15563, 2017 | | 2017 |
| A tool to predict post-transcriptional instability related to the dysregulation of the SETD2 histone methyltransferase in renal cell carcinoma (RCC). MD Champion, H Yan, J Evans, J Nie, JH Lee, JI Davila, R Moore, ... Journal of Clinical Oncology 32 (15_suppl), 11072-11072, 2014 | | 2014 |
| Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a … AP Fay, DJ Kwiatkowski, KP Gray, A Thorner, BI Rini, N Agarwal, TH Ho, ... Journal of Clinical Oncology 33 (15_suppl), 4519-4519, 2015 | 7 | 2015 |
| Adjuvant antiangiogenic agents in post-nephrectomy renal cell carcinoma (RCC): A systematic review and meta-analysis. MB Sonbol, T Hilal, B Firwana, TH Ho, Z Wang, RW Joseph Journal of Clinical Oncology 36 (6_suppl), 689-689, 2018 | | 2018 |
